HM4: Assessing the value of innovative therapies: trends, challenges and learnings

5M4A9983_TOPRA Symposium 2022_Day 1_20221017

This session focused on the evolution of the European Medicines Agency (EMA) and The European Network for Health Technology Assessment (EUnetHTA) collaboration.

 This is member-only content

To read this article, SIGN IN NOW if you are a TOPRA member.

 

Not a TOPRA member yet? Join our global community before
30 September and get 3 month’s extra membership for only £20.

Join by 30 September to get this exclusive rate.

Five great reasons to become a TOPRA member:

  1. Great savings on our events and training.
  2. Be part of our dynamic international community.
  3. Contribute to the profession.
  4. Grow your skills and knowledge.
  5. Take your career to the next level.

Have you heard? Why not listen to one of our free podcasts to see what you’re missing?